FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2178783218> ?p ?o ?g. }

• W2178783218 endingPage "31658" @default.
• W2178783218 startingPage "31640" @default.
• W2178783218 abstract "A cellular model (SCCOHT-1) of the aggressive small cell hypercalcemic ovarian carcinoma demonstrated constitutive chemokine and growth factor production including HGF. A simultaneous presence of c-Met in 41% SCCOHT-1 cells suggested an autocrine growth mechanism. Expression of c-Met was also observed at low levels in the corresponding BIN-67 cell line (6.5%) and at high levels in ovarian adenocarcinoma cells (NIH:OVCAR-3 (84.4%) and SK-OV-3 (99.3%)). Immunohistochemistry of c-Met expression in SCCOHT tumors revealed a heterogeneous distribution between undetectable levels and 80%. Further characterization of SCCOHT-1 and BIN-67 cells by cell surface markers including CD90 and EpCAM demonstrated similar patterns with differences to the ovarian adenocarcinoma cells. HGF stimulation of SCCOHT-1 cells was associated with c-Met phosphorylation at Tyr1349 and downstream Thr202/Tyr204 phosphorylation of p44/42 MAP kinase. This HGF-induced signaling cascade was abolished by the c-Met inhibitor foretinib. Cell cycle analysis after foretinib treatment demonstrated enhanced G2 accumulation and increasing apoptosis within 72 h. Moreover, the IC50 of foretinib revealed 12.4 nM in SCCOHT-1 cells compared to 411 nM and 481 nM in NIH:OVCAR-3 and SK-OV-3 cells, respectively, suggesting potential therapeutic effects. Indeed, SCCOHT-1 and BIN-67 tumor xenografts in NODscid mice exhibited an approximately 10-fold and 5-fold reduced tumor size following systemic application of foretinib, respectively. Furthermore, foretinib-treated tumors revealed a significantly reduced vascularization and little if any c-Met-mediated signal transduction. Similar findings of reduced proliferative capacity and declined tumor size were observed after siRNA-mediated c-Met knock-down in SCCOHT-1 cells demonstrating that in vivo inhibition of these pathways contributed to an attenuation of SCCOHT tumor growth." @default.
• W2178783218 created "2016-06-24" @default.
• W2178783218 creator A5001140861 @default.
• W2178783218 creator A5008727204 @default.
• W2178783218 creator A5011610563 @default.
• W2178783218 creator A5036956314 @default.
• W2178783218 creator A5057185329 @default.
• W2178783218 creator A5057665574 @default.
• W2178783218 creator A5073993016 @default.
• W2178783218 creator A5082261491 @default.
• W2178783218 date "2015-09-30" @default.
• W2178783218 modified "2023-10-16" @default.
• W2178783218 title "c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations" @default.
• W2178783218 cites W105513083 @default.
• W2178783218 cites W1481133043 @default.
• W2178783218 cites W1566837890 @default.
• W2178783218 cites W1655853170 @default.
• W2178783218 cites W171349864 @default.
• W2178783218 cites W1901154960 @default.
• W2178783218 cites W1969613291 @default.
• W2178783218 cites W1979568379 @default.
• W2178783218 cites W1988186967 @default.
• W2178783218 cites W1991219544 @default.
• W2178783218 cites W1996762218 @default.
• W2178783218 cites W2002934996 @default.
• W2178783218 cites W2011284860 @default.
• W2178783218 cites W2013397769 @default.
• W2178783218 cites W2014089553 @default.
• W2178783218 cites W2018748212 @default.
• W2178783218 cites W2023414851 @default.
• W2178783218 cites W2027577263 @default.
• W2178783218 cites W2031426180 @default.
• W2178783218 cites W2034855235 @default.
• W2178783218 cites W2039949690 @default.
• W2178783218 cites W2056751212 @default.
• W2178783218 cites W2058644395 @default.
• W2178783218 cites W2059143304 @default.
• W2178783218 cites W2059154675 @default.
• W2178783218 cites W2062110561 @default.
• W2178783218 cites W2063731707 @default.
• W2178783218 cites W2070369494 @default.
• W2178783218 cites W2077444028 @default.
• W2178783218 cites W2081781537 @default.
• W2178783218 cites W2086843919 @default.
• W2178783218 cites W2098586737 @default.
• W2178783218 cites W2101907683 @default.
• W2178783218 cites W2111005353 @default.
• W2178783218 cites W2111842868 @default.
• W2178783218 cites W2116095691 @default.
• W2178783218 cites W2118087314 @default.
• W2178783218 cites W2118564910 @default.
• W2178783218 cites W2125836866 @default.
• W2178783218 cites W2130921495 @default.
• W2178783218 cites W2134735372 @default.
• W2178783218 cites W2136390065 @default.
• W2178783218 cites W2141259177 @default.
• W2178783218 cites W2145261297 @default.
• W2178783218 cites W2145489725 @default.
• W2178783218 cites W2147073277 @default.
• W2178783218 cites W2152953590 @default.
• W2178783218 cites W2155127143 @default.
• W2178783218 cites W2167347313 @default.
• W2178783218 cites W2169909056 @default.
• W2178783218 cites W2170461821 @default.
• W2178783218 cites W2411903429 @default.
• W2178783218 cites W2418573008 @default.
• W2178783218 cites W92832180 @default.
• W2178783218 doi "https://doi.org/10.18632/oncotarget.5151" @default.
• W2178783218 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4741630" @default.
• W2178783218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26436697" @default.
• W2178783218 hasPublicationYear "2015" @default.
• W2178783218 type Work @default.
• W2178783218 sameAs 2178783218 @default.
• W2178783218 citedByCount "19" @default.
• W2178783218 countsByYear W21787832182016 @default.
• W2178783218 countsByYear W21787832182017 @default.
• W2178783218 countsByYear W21787832182018 @default.
• W2178783218 countsByYear W21787832182019 @default.
• W2178783218 countsByYear W21787832182020 @default.
• W2178783218 countsByYear W21787832182021 @default.
• W2178783218 crossrefType "journal-article" @default.
• W2178783218 hasAuthorship W2178783218A5001140861 @default.
• W2178783218 hasAuthorship W2178783218A5008727204 @default.
• W2178783218 hasAuthorship W2178783218A5011610563 @default.
• W2178783218 hasAuthorship W2178783218A5036956314 @default.
• W2178783218 hasAuthorship W2178783218A5057185329 @default.
• W2178783218 hasAuthorship W2178783218A5057665574 @default.
• W2178783218 hasAuthorship W2178783218A5073993016 @default.
• W2178783218 hasAuthorship W2178783218A5082261491 @default.
• W2178783218 hasBestOaLocation W21787832181 @default.
• W2178783218 hasConcept C121608353 @default.
• W2178783218 hasConcept C190283241 @default.
• W2178783218 hasConcept C2781182431 @default.
• W2178783218 hasConcept C502942594 @default.
• W2178783218 hasConcept C54355233 @default.
• W2178783218 hasConcept C55493867 @default.
• W2178783218 hasConcept C86803240 @default.
• W2178783218 hasConceptScore W2178783218C121608353 @default.

• next